Effects of hyperparathyroidism on blood lead concentrations in man. 1993

J D Osterloh, and O H Clark
Department of Laboratory Medicine, University of California, San Francisco 94143.

To investigate whether hyperparathyroidism has an effect on blood lead (Pb) concentrations and whether parathyroidectomy will alter blood Pb concentrations, we studied 15 subjects with primary hyperparathyroidism (HPTH) and 7 control subjects with thyroid nodules (TC). Blood Pb concentrations were determined several weeks prior to surgery and then again 4 months later. A reference group (REF) of nonsurgical lab/office workers was examined over the same periods of time. Initial mean blood Pb concentrations were 6.6 +/- 2.8, 6.0 +/- 2.9, and 5.0 +/- 1.7 micrograms/dl for the HPTH, TC, and REF groups (not significantly different), respectively. The mean percentage changes in blood Pb (before vs after) were -13.9, -4.9, and -6.1%. While the paired changes in blood Pb concentrations within the HPTH group were significant (P < 0.05), the percentage changes compared to either of the TC or REF groups were not significantly different. The percentage change in blood Pb correlated with the percentage change in serum calcium across all subjects (r = 0.5176, P = 0.0024, n = 24), although this correlation was not significant within any group alone. The HPTH group demonstrated expected changes in serum calcium, parathyroid hormone, and alkaline phosphatase concentrations. Three of the HPTH subjects received a CaNa2 EDTA chelation challenge (1 g intramuscularly) before and 4 months after surgery. Chelated amounts of Pb (microgram/24 hr before vs after) were 52 vs 38, 42 vs 47, and 60 vs 34. These data indicate that in the high bone turnover state of hyperparathyroidism that Pb concentrations in the blood-soft tissue compartment, and probably Pb mass, are not likely to be different from other individuals. Also parathyroidectomy results in a lowering of blood Pb concentrations possibly due to parallel movements of calcium.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D007854 Lead A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.

Related Publications

J D Osterloh, and O H Clark
January 2014, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),
J D Osterloh, and O H Clark
April 1987, Atherosclerosis,
J D Osterloh, and O H Clark
March 1983, Journal of epidemiology and community health,
J D Osterloh, and O H Clark
December 1986, American journal of veterinary research,
J D Osterloh, and O H Clark
May 1981, Nature,
J D Osterloh, and O H Clark
October 1948, Lancet (London, England),
J D Osterloh, and O H Clark
October 1978, Bulletin of environmental contamination and toxicology,
J D Osterloh, and O H Clark
December 1992, Regulatory toxicology and pharmacology : RTP,
J D Osterloh, and O H Clark
August 1994, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!